UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

Annals of oncology, 2017-08, Vol.28 (8), p.1988-1995

2017

Volltextzugriff (PDF)

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

Nature communications, 2018-08, Vol.9 (1), p.3196-15, Article 3196

2018

Volltextzugriff (PDF)

Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation

Oncogene, 2014-03, Vol.33 (11), p.1438-1447

2014

Volltextzugriff (PDF)

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

The New England journal of medicine, 2022-06, Vol.386 (25), p.2363-2376

2022

Volltextzugriff (PDF)

CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii544-viii545

2018

Volltextzugriff (PDF)

Quantitative Measurement of BIM Protein in Lung Cancer

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S11-S11

2014

Volltextzugriff (PDF)

1434P Machine learning features derived from spatial interaction of immune cell families are associated with survival in NSCLC patients post-immunotherapy

Annals of oncology, 2023-10, Vol.34, p.S816-S816

2023

Volltextzugriff (PDF)

P1.04-23 Characterizing the Tumor Immune Microenvironment of Non-Small Cell Lung Carcinoma in People Living with HIV Using Imaging Mass Cytometry

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S448-S448

2019

Volltextzugriff (PDF)

P15.04 A Phase I/IB Trial of Pembrolizumab and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S345-S345

2021

Volltextzugriff (PDF)

Évaluation de la machinerie de présentation antigénique associé au MHC de classe I dans le cancer bronchique non à petites cellules (CBNPC)

Revue des maladies respiratoires actualités, 2024-01, Vol.16 (1), p.271

2024

Volltextzugriff (PDF)

MA25.02 Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S350-S351

2019

Volltextzugriff (PDF)

MA15.05 Computerized Measurements of Cellular Diversity on H&E Tissue Are Prognostic of OS and Associated with Mutational Status in NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S310-S310

2019

Volltextzugriff (PDF)

PUB024 Clusters Spatial Arrangement of Tumor Infiltrating Lymphocyte and Cancer Nuclei Predicts Recurrence in Early Stage Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2372-S2373

2017

Volltextzugriff (PDF)

1503TiPCheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-07-09

2016

Volltextzugriff (PDF)

P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S528-S528

2018

Volltextzugriff (PDF)

In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers

Annals of oncology, 2017-12, Vol.28, p.xi5-xi5

2017

Volltextzugriff (PDF)

MA 13.03 Quantitative Spatial Profiling of PD-1/PD-L1 Interaction Predicts Response to Adjuvant Chemotherapy Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1852-S1852

2017

Volltextzugriff (PDF)

MA 15.06 ERBB Receptor Feedback Inhibitor-1 Alterations in Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1863-S1863

2017

Volltextzugriff (PDF)

Quantitative Measurement of BIM Protein in Lung Cancer: Diagnosis/Staging

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S11-S11

2014

Volltextzugriff (PDF)

Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration

Antioxidants & redox signaling, 2009-02, Vol.11 (2), p.369-399

2009

Volltextzugriff (PDF)

Abstract P2-10-02: PD-L1 protein expression is a prognostic biomarker in breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-10-02

2013

Volltextzugriff (PDF)

2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592

Immuno-oncology technology, 2022-12, Vol.16, p.100107, Article 100107

2022

Volltextzugriff (PDF)

MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S294-S295

2019

Volltextzugriff (PDF)

Pin1 modulates ER[alpha] levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation

Oncogene, 2014-03, Vol.33 (11), p.1438

2014

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(41)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC

Quantitative Measurement of BIM Protein in Lung Cancer

1434P Machine learning features derived from spatial interaction of immune cell families are associated with survival in NSCLC patients post-immunotherapy

P1.04-23 Characterizing the Tumor Immune Microenvironment of Non-Small Cell Lung Carcinoma in People Living with HIV Using Imaging Mass Cytometry

P15.04 A Phase I/IB Trial of Pembrolizumab and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung Cancer

Évaluation de la machinerie de présentation antigénique associé au MHC de classe I dans le cancer bronchique non à petites cellules (CBNPC)

MA25.02 Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung Cancer

MA15.05 Computerized Measurements of Cellular Diversity on H&E Tissue Are Prognostic of OS and Associated with Mutational Status in NSCLC

PUB024 Clusters Spatial Arrangement of Tumor Infiltrating Lymphocyte and Cancer Nuclei Predicts Recurrence in Early Stage Non-Small Cell Lung Cancer

1503TiPCheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC

Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker

P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI

In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers

MA 13.03 Quantitative Spatial Profiling of PD-1/PD-L1 Interaction Predicts Response to Adjuvant Chemotherapy Non–Small-Cell Lung Cancer

MA 15.06 ERBB Receptor Feedback Inhibitor-1 Alterations in Non-Small Cell Lung Cancer

Quantitative Measurement of BIM Protein in Lung Cancer: Diagnosis/Staging

Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration

Abstract P2-10-02: PD-L1 protein expression is a prognostic biomarker in breast cancer

2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592

MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC

Pin1 modulates ER[alpha] levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation

Suchergebnisse filtern